

Dexamethasone in Hospitalized Patients with Covid-19

The RECOVERY Collaborative Group*

ABSTRACT

BACKGROUND

Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.

METHODS

In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the final results of this assessment.

RESULTS

A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; $P < 0.001$). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55).

CONCLUSIONS

In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936; ISRCTN number, 50189673.)

The members of the writing committee (Peter Horby, F.R.C.P., Wei Shen Lim, F.R.C.P., Jonathan R. Emberson, Ph.D., Marion Mafham, M.D., Jennifer L. Bell, M.Sc., Louise Linsell, D.Phil., Natalie Staplin, Ph.D., Christopher Brightling, F.Med.Sci., Andrew Ustianowski, Ph.D., Einas Elmahi, M.Phil., Benjamin Prudon, F.R.C.P., Christopher Green, D.Phil., Timothy Felton, Ph.D., David Chadwick, Ph.D., Kanchan Rege, F.R.C.Path., Christopher Fegan, M.D., Lucy C. Chappell, Ph.D., Saul N. Faust, F.R.C.P.C.H., Thomas Jaki, Ph.D., Katie Jeffery, Ph.D., Alan Montgomery, Ph.D., Kathryn Rowan, Ph.D., Edmund Juszczak, M.Sc., J. Kenneth Baillie, M.D., Ph.D., Richard Haynes, D.M., and Martin J. Landray, F.R.C.P.) assume responsibility for the overall content and integrity of this article.

The affiliations of the members of the writing committee are listed in the Appendix. Address reprint requests to Drs. Horby and Landray at RECOVERY Central Coordinating Office, Richard Doll Bldg., Old Road Campus, Roosevelt Dr., Oxford OX3 7LF, United Kingdom, or at recoverytrial@ndph.ox.ac.uk.

*A complete list of collaborators in the RECOVERY trial is provided in the Supplementary Appendix, available at NEJM.org.

Drs. Horby, Lim, and Emberson and Drs. Haynes and Landray contributed equally to this article.

A preliminary version of this article was published on July 17, 2020, at NEJM.org.

N Engl J Med 2021;384:693-704.

DOI: 10.1056/NEJMoa2021436

Copyright © 2020 Massachusetts Medical Society.



SEVERE ACUTE RESPIRATORY SYNDROME coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (Covid-19), emerged in China in late 2019 from a zoonotic source.¹ The majority of Covid-19 cases either are asymptomatic or result in only mild disease. However, in a substantial percentage of patients, a respiratory illness requiring hospital care develops,² and such infections can progress to critical illness with hypoxemic respiratory failure requiring prolonged ventilatory support.³⁻⁶ Among patients with Covid-19 who were admitted to hospitals in the United Kingdom in the first half of 2020, the case fatality rate was approximately 26% overall and more than 37% among patients who were undergoing invasive mechanical ventilation.⁷ Although remdesivir has been shown to shorten the time until recovery in hospitalized patients,⁸ no therapeutic agents have been shown to reduce mortality.

The pathophysiological features of severe Covid-19 are dominated by an acute pneumonic process with extensive radiologic opacity and, on autopsy, diffuse alveolar damage, inflammatory infiltrates, and microvascular thrombosis.⁹ In other severe viral pneumonias, such as highly pathogenic avian influenza,¹⁰ SARS,¹¹ and pandemic and seasonal influenza,¹² the host immune response is thought to play a key role in the pathophysiology of organ failure. Inflammatory organ injury may occur in severe Covid-19, with a subgroup of patients having markedly elevated levels of inflammatory markers, including C-reactive protein, ferritin, interleukin-1, and interleukin-6.^{6,13,14} Several therapeutic interventions have been proposed to mitigate inflammatory organ injury in viral pneumonia, but the value of glucocorticoids has been widely debated.^{15,16}

Although one small trial has reported improved clinical outcomes in patients with Covid-19 who were given methylprednisolone,¹⁷ the absence of reliable evidence from large-scale randomized clinical trials means there is uncertainty about the effectiveness of glucocorticoids in patients with Covid-19. Many guidelines for the treatment of such patients have stated that glucocorticoids were either contraindicated or not recommended,¹⁸ although in China, glucocorticoids have been recommended for severe cases.¹⁹ However, in the first 6 months of the pandemic, practice varied widely across the world: in some series, as many

as 50% of patients were treated with glucocorticoids.^{20,21} Here, we report the results of the controlled, open-label Randomized Evaluation of Covid-19 Therapy (RECOVERY) trial of dexamethasone in patients hospitalized with Covid-19.

METHODS

TRIAL DESIGN AND OVERSIGHT

The RECOVERY trial was designed to evaluate the effects of potential treatments in patients hospitalized with Covid-19 at 176 National Health Service organizations in the United Kingdom and was supported by the National Institute for Health Research Clinical Research Network. (Details regarding this trial are provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.) The trial is being coordinated by the Nuffield Department of Population Health at the University of Oxford, the trial sponsor. Although the randomization of patients to receive dexamethasone, hydroxychloroquine, lopinavir–ritonavir, azithromycin, convalescent plasma, or tocilizumab has now been stopped, the trial continues randomization to other treatments, including REGN-COV2 (a combination of two monoclonal antibodies directed against the SARS-CoV-2 spike protein), aspirin, colchicine, or usual care alone.

Hospitalized patients were eligible for the trial if they had clinically suspected or laboratory-confirmed SARS-CoV-2 infection and no medical history that might, in the opinion of the attending clinician, put patients at substantial risk if they were to participate in the trial. Initially, recruitment was limited to patients who were at least 18 years of age, but the age limit was removed starting on May 9, 2020. Pregnant or breast-feeding women were eligible.

Written informed consent was obtained from all the patients or from a legal representative if they were unable to provide consent. The trial was conducted in accordance with the principles of the Good Clinical Practice guidelines of the International Conference on Harmonisation and was approved by the U.K. Medicines and Healthcare Products Regulatory Agency and the Cambridge East Research Ethics Committee. The protocol with its statistical analysis plan is available at NEJM.org and on the trial website at www.recoverytrial.net.

The initial version of the manuscript was drafted by the first and last authors, developed by the writing committee, and approved by all members of the trial steering committee. The funders had no role in the analysis of the data, in the preparation or approval of the manuscript, or in the decision to submit the manuscript for publication. The first and last members of the writing committee vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol and statistical analysis plan.

RANDOMIZATION

We collected baseline data using a Web-based case-report form that included demographic data, the level of respiratory support, major coexisting illnesses, suitability of the trial treatment for a particular patient, and treatment availability at the trial site. Randomization was performed with the use of a Web-based system with concealment of the trial-group assignment. Eligible and consenting patients were assigned in a 2:1 ratio to receive either the usual standard of care alone or the usual standard of care plus oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days (or until hospital discharge if sooner) or to receive one of the other suitable and available treatments that were being evaluated in the trial.

For some patients, dexamethasone was unavailable at the hospital at the time of enrollment or was considered by the managing physician to be either definitely indicated or definitely contraindicated. These patients were excluded from the randomized comparison between dexamethasone and usual care. The randomly assigned treatment was prescribed by the treating clinician. Patients and local members of the trial staff were aware of the assigned treatments.

PROCEDURES

A single online follow-up form was to be completed by the local trial staff when each patient was discharged or had died or at 28 days after randomization, whichever occurred first. Information was recorded regarding the patients' adherence to the assigned treatment, receipt of other treatments for Covid-19, duration of admission, receipt of respiratory support (with duration and type), receipt of renal dialysis or

hemofiltration, and vital status (including the cause of death). In addition, we obtained routine health care and registry data, including information on vital status (with date and cause of death), discharge from the hospital, and respiratory and renal support therapy.

OUTCOME MEASURES

The primary outcome was all-cause mortality within 28 days after randomization; further analyses were specified at 6 months. Secondary outcomes were the time until discharge from the hospital and, among patients not receiving invasive mechanical ventilation at the time of randomization, subsequent receipt of invasive mechanical ventilation (including extracorporeal membrane oxygenation) or death. Other prespecified clinical outcomes included cause-specific mortality, receipt of renal dialysis or hemofiltration, major cardiac arrhythmia (recorded in a subgroup), and receipt and duration of ventilation. Among those receiving invasive mechanical ventilation at the time of randomization, the outcome of successful cessation of invasive mechanical ventilation was defined as cessation within (and survival to) 28 days. All information presented in this report is based on a data cutoff of December 14, 2020. Information regarding the primary and secondary outcomes is complete for 99.9% of trial participants.

STATISTICAL ANALYSIS

As stated in the protocol, appropriate sample sizes could not be estimated when the trial was being planned at the start of the Covid-19 pandemic. As the trial progressed, the trial steering committee, whose members were unaware of the results of the trial comparisons, determined that if 28-day mortality was 20%, then the enrollment of at least 2000 patients in the dexamethasone group and 4000 in the usual care group would provide a power of at least 90% at a two-sided P value of 0.01 to detect a clinically relevant proportional reduction of 20% (an absolute difference of 4 percentage points) between the two groups. Consequently, on June 8, 2020, the steering committee closed recruitment to the dexamethasone group, since enrollment had exceeded 2000 patients.

For the primary outcome of 28-day mortality, the hazard ratio from Cox regression was used

to estimate the mortality rate ratio. Kaplan–Meier survival curves were constructed to show cumulative mortality over the 28-day period. Cox regression was also used to analyze the secondary outcome of hospital discharge within 28 days and the outcome of successful cessation of invasive mechanical ventilation. For both of these outcomes, data for patients who had died during hospitalization were censored on day 29. For the prespecified composite secondary outcome of invasive mechanical ventilation or death within 28 days (among patients who were not receiving invasive mechanical ventilation at randomization), the precise date of invasive mechanical ventilation was not available, so a log-binomial regression model was used to estimate the risk ratio. Risk ratios were also estimated for the outcomes of receipt of noninvasive or invasive mechanical ventilation (among patients who were not receiving oxygen or invasive mechanical ventilation at the time of randomization) and receipt of renal-replacement therapy (among those not receiving such therapy at the time of randomization).

Through the play of chance in the unstratified randomization, the mean age was 1.1 years older among patients in the dexamethasone group than among those in the usual care group (Table 1). To account for this imbalance in an important prognostic factor, estimates of rate and risk ratios were adjusted for the baseline age in three categories (<70 years, 70 to 79 years, and ≥80 years). This adjustment was not specified in the first version of the statistical analysis plan but was added once the imbalance in age became apparent. Results without age adjustment (corresponding to the first version of the analysis plan) are provided in the Supplementary Appendix.

Prespecified analyses of the primary outcome were performed in six subgroups, as defined by characteristics at randomization: age, sex, race, level of respiratory support, days since symptom onset, and predicted 28-day mortality risk. In prespecified subgroups, we estimated rate ratios (or risk ratios in some analyses) and their confidence intervals using regression models that included an interaction term between the treatment assignment and the subgroup of interest. Chi-square tests for heterogeneity or linear trend across the subgroup-specific log estimates were

then performed in accordance with the prespecified plan.

All P values are two-sided and are shown without adjustment for multiple testing. All analyses were performed according to the intention-to-treat principle. The full database is held by the trial team, which collected the data from trial sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford.

RESULTS

PATIENTS

Of the 11,303 patients who underwent randomization from March 19 to June 8, 2020, a total of 9355 (83%) were eligible to receive dexamethasone (i.e., the drug was available in the hospital at the time and the patient had no known indication for or contraindication to dexamethasone). Of these patients, 6425 underwent randomization to receive either dexamethasone (2104 patients) or usual care alone (4321 patients) (Fig. 1). The remaining patients were randomly assigned to one of the other treatment groups being evaluated in the trial.

The mean (\pm SD) age of the patients in this comparison was 66.1 \pm 15.7 years, 36% of the patients were female, and 18% were Black, Asian, or from a minority ethnic group (Table 1 and Table S1 in the Supplementary Appendix). A history of diabetes was present in 24% of the patients, heart disease in 27%, and chronic lung disease in 21%, with 56% having at least one major coexisting illness recorded. In this analysis, 89% of the patients had laboratory-confirmed SARS-CoV-2 infection. At randomization, 16% were receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, 60% were receiving oxygen only (with or without noninvasive ventilation), and 24% were receiving neither.

In the dexamethasone group, 95% of the patients received at least one dose of a glucocorticoid (Table S2). The median duration of treatment was 7 days (interquartile range, 3 to 10). In the usual care group, 8% of the patients received a glucocorticoid as part of their clinical care. The use of azithromycin or another macrolide antibiotic during the follow-up period was similar in the dexamethasone group and the usual care group (24% vs. 26%), and 0 to 3% of patients

Table 1. Characteristics of the Patients at Baseline, According to Treatment Assignment and Level of Respiratory Support.*

Characteristic	Treatment Assignment		Respiratory Support Received at Randomization		
	Dexamethasone (N=2104)	Usual Care (N=4321)	No Receipt of Oxygen (N=1535)	Oxygen Only (N=3883)	Invasive Mechanical Ventilation (N=1007)
Age†					
Mean — yr	66.9±15.4	65.8±15.8	69.4±17.5	66.7±15.3	59.1±11.4
Distribution — no. (%)					
<70 yr	1141 (54)	2505 (58)	659 (43)	2149 (55)	838 (83)
70 to 79 yr	469 (22)	859 (20)	338 (22)	837 (22)	153 (15)
≥80 yr	494 (23)	957 (22)	538 (35)	897 (23)	16 (2)
Sex — no. (%)					
Male	1338 (64)	2749 (64)	891 (58)	2462 (63)	734 (73)
Female‡	766 (36)	1572 (36)	644 (42)	1421 (37)	273 (27)
Race or ethnic group — no. (%)§					
White	1550 (74)	3139 (73)	1221 (80)	2894 (75)	574 (57)
Black, Asian, or minority ethnic group	364 (17)	783 (18)	191 (12)	662 (17)	294 (29)
Unknown	190 (9)	399 (9)	123 (8)	327 (8)	139 (14)
Median no. of days since symptom onset (IQR)¶	8 (5–13)	9 (5–13)	6 (3–10)	9 (5–12)	13 (8–18)
Median no. of days since hospitalization (IQR)	2 (1–5)	2 (1–5)	2 (1–6)	2 (1–4)	5 (3–9)
Respiratory support received — no. (%)					
No oxygen	501 (24)	1034 (24)	1535 (100)	NA	NA
Oxygen only	1279 (61)	2604 (60)	NA	3883 (100)	NA
Invasive mechanical ventilation	324 (15)	683 (16)	NA	NA	1007 (100)
Previous coexisting disease — no. (%)					
Any of the listed conditions	1174 (56)	2417 (56)	911 (59)	2175 (56)	505 (50)
Diabetes	521 (25)	1025 (24)	342 (22)	950 (24)	254 (25)
Heart disease	586 (28)	1171 (27)	519 (34)	1074 (28)	164 (16)
Chronic lung disease	415 (20)	931 (22)	351 (23)	883 (23)	112 (11)
Tuberculosis	6 (<1)	19 (<1)	8 (1)	11 (<1)	6 (1)
HIV infection	12 (1)	20 (<1)	5 (<1)	21 (1)	6 (1)
Severe liver disease	37 (2)	82 (2)	32 (2)	72 (2)	15 (1)
Severe kidney impairment**	166 (8)	358 (8)	119 (8)	253 (7)	152 (15)
SARS-CoV-2 test result — no. (%)					
Positive	1865 (89)	3879 (90)	1340 (87)	3433 (88)	971 (96)
Negative	225 (11)	425 (10)	190 (12)	429 (11)	31 (3)
Test result not yet known	14 (1)	17 (<1)	5 (<1)	21 (1)	5 (<1)

* Plus-minus values are means ±SD. HIV denotes human immunodeficiency virus, IQR interquartile range, NA not applicable, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.

† There was a significant ($P=0.01$) difference in the mean age between patients in the dexamethasone group and those in the usual care group, but there were no significant differences between the groups in any other baseline characteristic.


‡ Among the women, 1 in the dexamethasone group and 3 in the usual care group were pregnant.

§ Race or ethnic group was recorded in the patient's electronic health record.

¶ Data regarding the number of days since symptom onset were missing for 4 patients in the dexamethasone group and 13 patients in the usual care group; these patients were excluded from estimates of the median number of days since onset.

|| Severe liver disease was defined as requiring ongoing specialist care.


** Severe kidney impairment was defined as an estimated glomerular filtration rate of less than 30 ml per minute per 1.73 m².



received hydroxychloroquine, lopinavir-ritonavir, or interleukin-6 antagonists during follow-up (Table S2). After remdesivir became available in the United Kingdom on May 26, 2020, the drug was administered to 3 patients before randomization and 2 patients during the follow-up period (Table S2).


PRIMARY OUTCOME

Mortality at 28 days was significantly lower in the dexamethasone group than in the usual care group, with deaths reported in 482 of 2104 patients (22.9%) and in 1110 of 4321 patients (25.7%), respectively (rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; $P < 0.001$).



(Fig. 2A). In a prespecified analysis according to the level of respiratory support that the patients were receiving at randomization, there was a trend showing the greatest absolute and proportional benefit among patients who were receiving invasive mechanical ventilation (11.6 by

chi-square test for trend) (Fig. 3). In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and in those receiving oxygen with-



out invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) (Fig. 2B and 2C). However, there was no clear effect of dexamethasone among patients who were not receiving any respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55) (Fig. 2D). The results were similar in a post hoc exploratory analysis restricted to the 5744 patients (89.4%) with a positive SARS-CoV-2 test result. Likewise, sensitivity analyses without adjustment for age resulted in similar findings (Table S3).

Patients who were receiving invasive mechanical ventilation at randomization were on average 10 years younger than those not receiving any respiratory support and had a history of symptoms before randomization for an average of 7 days longer (Table 1 and Table S4). The age-adjusted absolute reductions in 28-day mortality associated with the use of dexamethasone were 12.3 percentage points (95% CI, 6.2 to 17.6) among the patients who were receiving invasive mechanical ventilation and 4.2 percentage points (95% CI, 1.4 to 6.7) among those receiving oxygen only.

Patients with a longer duration of symptoms (who were more likely to have been receiving invasive mechanical ventilation at randomization) had a greater mortality benefit in response to treatment with dexamethasone. The receipt of dexamethasone was associated with a reduction in 28-day mortality among those with symptoms for more than 7 days but not among those with

a more recent symptom onset (12.4 by chi-square test for trend) (Fig. S1).

SECONDARY OUTCOMES

Patients in the dexamethasone group had a shorter duration of hospitalization than those in the usual care group (median, 12 days vs. 13 days) and a greater probability of discharge alive within 28 days (rate ratio, 1.10; 95% CI, 1.03 to 1.17) (Table 2). The greatest effect regarding discharge within 28 days was seen among patients who were receiving invasive mechanical ventilation at randomization (11.7 by chi-square test for trend) (Fig. S2A and Fig. S3).

Among the patients who were not receiving invasive mechanical ventilation at randomization, the number of patients who progressed to the prespecified composite secondary outcome of invasive mechanical ventilation or death was lower in the dexamethasone group than in the usual care group (risk ratio, 0.93; 95% CI, 0.85 to 1.01) (Table 2). This effect was greater among the patients who were receiving oxygen at randomization (6.3 by chi-square test for trend) (Fig. S2B). Other prespecified analyses of the effects of dexamethasone on these secondary outcomes among different categories of patients are shown in Figures S4 and S5.

OTHER PRESPECIFIED CLINICAL OUTCOMES

Among patients who were not receiving invasive mechanical ventilation at randomization, the risk of progression to invasive mechanical ventilation

Table 2. Primary and Secondary Outcomes and Prespecified Subsidiary Clinical Outcomes.

Outcome	Dexamethasone (N=2104)	Usual Care (N=4321)	Rate or Risk Ratio (95% CI)*
<i>no./total no. of patients (%)</i>			
Primary outcome			
Death at 28 days	482/2104 (22.9)	1110/4321 (25.7)	0.83 (0.75–0.93)
Secondary outcomes			
Discharged from hospital within 28 days	1416/2104 (67.3)	2748/4321 (63.6)	1.10 (1.03–1.17)
Invasive mechanical ventilation or death†	462/1780 (26.0)	1003/3638 (27.6)	0.93 (0.85–1.01)
Invasive mechanical ventilation	110/1780 (6.2)	298/3638 (8.2)	0.79 (0.64–0.97)
Death	387/1780 (21.7)	827/3638 (22.7)	0.93 (0.84–1.03)
Subsidiary clinical outcomes			
Use of ventilation‡	25/501 (5.0)	65/1034 (6.3)	0.84 (0.54–1.32)
Noninvasive ventilation	20/501 (4.0)	57/1034 (5.5)	0.77 (0.47–1.26)
Invasive mechanical ventilation	9/501 (1.8)	19/1034 (1.8)	1.07 (0.49–2.34)
Successful cessation of invasive mechanical ventilation§	160/324 (49.4)	268/683 (39.2)	1.47 (1.20–1.78)
Renal-replacement therapy¶	89/2034 (4.4)	314/4194 (7.5)	0.61 (0.48–0.76)

* Rate ratios have been adjusted for age with respect to the outcomes of 28-day mortality, hospital discharge, and successful cessation of invasive mechanical ventilation. Risk ratios have been adjusted for age with respect to the outcomes of invasive mechanical ventilation or death (and its subcomponents), use of ventilation, and renal-replacement therapy.

† Excluded from this category are patients who were receiving invasive mechanical ventilation at randomization.

‡ Excluded from this category are patients who were receiving oxygen (since some patients in this category were receiving noninvasive ventilation) or invasive mechanical ventilation at randomization.

§ Excluded from this category are patients who were not receiving invasive mechanical ventilation at randomization.

¶ Excluded from this category are patients who were receiving renal-replacement therapy at randomization.

was lower in the dexamethasone group than in the usual care group (risk ratio, 0.79; 95% CI, 0.64 to 0.97) (Table 2). Among those who were receiving invasive mechanical ventilation at randomization, successful cessation of invasive mechanical ventilation was more likely in the dexamethasone group than in the usual care group (rate ratio, 1.47; 95% CI, 1.20 to 1.78) (Table 2 and Fig. S6). Among the patients who were not receiving renal-replacement therapy (renal dialysis or hemofiltration) at randomization, the number of patients who received this treatment within 28 days was lower in the dexamethasone group than in the usual care group (risk ratio, 0.61; 95% CI, 0.48 to 0.76) (Table 2).

Most deaths were due to Covid-19, and such deaths were less frequent in the dexamethasone group than in the usual care group (Table S5). The incidence of death from other causes was similar in the dexamethasone group and the usual care group. In the subgroup of patients with available data, the incidence of new cardiac

arrhythmia was similar in the dexamethasone group and the usual care group (Table S6). There were four reports of a serious adverse reaction that was deemed by the investigators to be related to dexamethasone: two of hyperglycemia, one of gastrointestinal hemorrhage, and one of psychosis (all recognized adverse effects of glucocorticoids).

DISCUSSION

Our results show that among hospitalized patients with Covid-19, the use of dexamethasone for up to 10 days resulted in lower 28-day mortality than usual care in patients who were receiving invasive mechanical ventilation at randomization (by 12.3 age-adjusted percentage points, a proportional reduction of approximately one third) and those who were receiving oxygen without invasive mechanical ventilation (by 4.2 age-adjusted percentage points, a proportional reduction of approximately one fifth). However,

there was no evidence that dexamethasone provided any benefit among patients who were not receiving respiratory support at randomization, and the results were consistent with possible harm in this subgroup. The benefit was also clear in patients who were being treated more than 7 days after symptom onset, when inflammatory lung damage is likely to have been more common. A subsequent meta-analysis of seven trials of glucocorticoids for critically ill patients with Covid-19, including RECOVERY, has confirmed the findings of our trial.²² Our results also show that among the patients who were receiving oxygen, the use of dexamethasone was associated with a lower risk of invasive mechanical ventilation or, for those already receiving invasive mechanical ventilation, a greater chance of successful cessation. In both these groups, the use of dexamethasone increased the chance of being discharged from the hospital alive within 28 days.

The RECOVERY trial was designed to provide a rapid and robust assessment of the effect of readily available potential treatments for Covid-19 on 28-day mortality. Approximately 10% of all hospitalized patients with Covid-19 in the United Kingdom were enrolled in the trial, and mortality in the usual care group was consistent with the overall case fatality rate for hospitalized patients with Covid-19 in the United Kingdom at the time that the dexamethasone comparison was active.⁷ Only essential data were collected at hospital sites, with additional information (including longer-term mortality) ascertained through linkage with routine data sources. We did not collect information on physiologic, laboratory, or virologic measures. The protocol combines the methods that were used in large, simple trials of treatments for acute myocardial infarction in the 1980s with the opportunities provided by digital health care in the 2020s.²³⁻²⁵ The trial has progressed rapidly, as is essential for studies during epidemics.²⁶ The preliminary results for dexamethasone were announced on June 16, 2020, less than 100 days after the protocol was first drafted, and were adopted into U.K. practice later the same day.²⁷

Glucocorticoids have been widely used in syndromes closely related to Covid-19, including SARS, Middle East respiratory syndrome (MERS), severe influenza, and community-acquired pneu-

monia. However, the evidence to support or discourage the use of glucocorticoids under these conditions has been weak owing to the lack of data from sufficiently powered randomized, controlled trials.²⁸⁻³¹ In addition, the evidence base has suffered from heterogeneity in glucocorticoid doses, medical conditions, and disease severity. It is likely that the beneficial effect of glucocorticoids in severe viral respiratory infections is dependent on the selection of the right dose, at the right time, in the right patient. High doses may be more harmful than helpful, as may such treatment given at a time when control of viral replication is paramount and inflammation is minimal. Slower clearance of viral RNA has been observed in patients with SARS, MERS, and influenza who were treated with systemic glucocorticoids, but the clinical significance of these findings is unknown.^{29,32,33} Unlike with SARS, in which viral replication peaks in the second week of illness,³⁴ viral shedding in SARS-CoV-2 appears to be higher early in the illness and declines thereafter.³⁵⁻³⁸ The greater mortality benefit of dexamethasone in patients with Covid-19 who are receiving respiratory support and among those recruited after the first week of their illness suggests that at that stage the disease may be dominated by immunopathological elements, with active viral replication playing a secondary role. This hypothesis would caution against extrapolation of the effect of dexamethasone in patients with Covid-19 to patients with other viral respiratory diseases with a different natural history.

The RECOVERY trial provides evidence that treatment with dexamethasone at a dose of 6 mg once daily for up to 10 days reduces 28-day mortality in patients with Covid-19 who are receiving respiratory support. We found no benefit (and the possibility of harm) among patients who did not require oxygen. Before the completion of the trial, many Covid-19 treatment guidelines stated that the use of glucocorticoids was either contraindicated or not recommended.¹⁸ Dexamethasone is on the list of essential medicines of the World Health Organization and is readily available worldwide at low cost. Guidelines issued by the U.K. chief medical officers, the European Medicines Agency, the World Health Organization, and the National Institutes of Health in the United States have been updated to recommend

the use of glucocorticoids in patients hospitalized with Covid-19 requiring oxygen with or without ventilatory support.^{27,39,40}

The views expressed in this article are those of the authors and do not necessarily reflect those of the National Health Service, the National Institute for Health Research, the Medical Research Council of United Kingdom Research and Innovation, or the Department of Health and Social Care.

Supported by a grant (MC_PC_19056) to the University of Oxford from the Medical Research Council of United Kingdom Research and Innovation and the National Institute for Health Research (NIHR); and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. Dr. Lim is supported by core funding provided by NIHR Nottingham Biomedical Research Centre, Dr. Felton by the NIHR Manchester Biomedical Research Centre, and Dr. Jaki by a grant (MC_UU_0002/14) from the UK Medical Research Council and by an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). Tocilizumab was provided free of charge for this study by Roche. AbbVie contributed some supplies of lopinavir–ritonavir for use in the trial. Regeneron contributed supplies of REGN-COV2 for use in the clinical trial. Other medications, including dexamethasone, that were used in the trial were supplied by the National Health Service (NHS).

Dr. Lim reports receiving grant support from Pfizer; Dr. Emberson, receiving grant support from Boehringer Ingelheim;

Dr. Mafham, receiving grant support and provision of materials from the Medicines Company/Novartis; Dr. Staplin, receiving grant support from Boehringer Ingelheim; Dr. Faust, receiving grant support, lecture fees, and advisory board fees, all paid to his institution, from Pfizer, advisory board fees, paid to his institution, from AstraZeneca, Seqirus, Sandoz, and MedImmune, grant support and advisory board fees, all paid to his institution, from Sanofi and Merck, and grant support, paid to his institution, from GSK and Johnson & Johnson; Dr. Haynes, receiving grant support from the Medicines Company and Boehringer Ingelheim; Dr. Landray, receiving grant support from Novartis, Boehringer Ingelheim, and Merck Sharp & Dohme. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

We thank the thousands of patients who participated in this trial; the doctors, nurses, pharmacists, other allied health professionals, and research administrators at 176 NHS hospital organizations across the United Kingdom, supported by staff at the NIHR Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health and Social Care, the Intensive Care National Audit and Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales, and Northern Ireland; and the members of the independent data monitoring committee: Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo, Ian Roberts, and Janet Wittes.

APPENDIX

The affiliations of the members of the writing committee are as follows: the Nuffield Department of Medicine (P.H.), Nuffield Department of Population Health (J.R.E., M.M., J.L.B., L.L., N.S., E.J., R.H., M.J.L.), and MRC Population Health Research Unit (J.R.E., N.S., R.H., M.J.L.), University of Oxford, the Oxford University Hospitals NHS Foundation Trust (K.J.), and National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (M.J.L.), Oxford, the Respiratory Medicine Department, Nottingham University Hospitals NHS Trust (W.S.L.), and the School of Medicine, University of Nottingham (A.M.), Nottingham, the Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester (C.B.), the Regional Infectious Diseases Unit, North Manchester General Hospital and University of Manchester (A.U.), and the University of Manchester and Manchester University NHS Foundation Trust (T.F.), Manchester, the Research and Development Department, Northampton General Hospital, Northampton (E.E.), the Department of Respiratory Medicine, North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees (B.P.), University Hospitals Birmingham NHS Foundation Trust and Institute of Microbiology and Infection, University of Birmingham, Birmingham (C.G.), the Centre for Clinical Infection, James Cook University Hospital, Middlesbrough (D.C.), the North West Anglia NHS Foundation Trust, Peterborough (K. Rege), the Department of Research and Development, Cardiff and Vale University Health Board, Cardiff (C.F.), the School of Life Course Sciences, King's College London (L.C.C.), and the Intensive Care National Audit and Research Centre (K. Rowan), London, the NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton (S.N.F.), the Department of Mathematics and Statistics, Lancaster University, Lancaster (T.J.), the MRC Biostatistics Unit, University of Cambridge, Cambridge (T.J.), and Roslin Institute, University of Edinburgh, Edinburgh (J.K.B.) — all in the United Kingdom.

REFERENCES

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020;382:727-33.
2. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis* 2020;20:669-77.
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054-62.
4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395:507-13.
5. Cao J, Tu W-J, Cheng W, et al. Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. *Clin Infect Dis* 2020;71:748-55.
6. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020;46:846-8.
7. Docherty AB, Harrison EM, Green CA, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020;369:m1985.
8. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. *N Engl J Med* 2020;383:1813-26.
9. Carsana L, Sonzogni A, Nasr A, et al.

- Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *Lancet Infect Dis* 2020;20:1135-40.
10. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. *Nat Med* 2006;12:1203-7.
 11. Wong CK, Lam CWK, Wu AKL, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol* 2004;136:95-103.
 12. Baillie JK, Digard P. Influenza — time to target the host? *N Engl J Med* 2013;369:191-3.
 13. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
 14. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science* 2020;368:473-4.
 15. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. *Lancet* 2020;395:683-4.
 16. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020;395:473-5.
 17. Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. June 18, 2020 (<https://www.medrxiv.org/content/10.1101/2020.06.17.20133579v1>). preprint.
 18. Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. *BMJ* 2020;369:m1936.
 19. Zhao JP, Hu Y, Du RH, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. *Zhonghua Jie He He Hu Xi Za Zhi* 2020;43:183-4. (In Chinese.)
 20. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061-9.
 21. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020;368:m606.
 22. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. *JAMA* 2020;324:1330-41.
 23. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? *Stat Med* 1984;3:409-22.
 24. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. *Lancet* 1988;2:349-60.
 25. Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. *N Engl J Med* 2020;382:674-8.
 26. Rojek AM, Horby PW. Modernising epidemic science: enabling patient-centred research during epidemics. *BMC Med* 2016;14:212.
 27. Whitty C. Dexamethasone in the treatment of COVID-19: implementation and management of supply for treatment in hospitals. London: Medicines and Healthcare Products Regulatory Agency, June 16, 2020 (<https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103054>).
 28. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006;3(9):e343.
 29. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. *Am J Respir Crit Care Med* 2018;197:757-67.
 30. Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. *Crit Care Med* 2020;48(2):e98-e106.
 31. Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. *Ann Intern Med* 2015;163:519-28.
 32. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *J Clin Virol* 2004;31:304-9.
 33. Lee N, Chan PKS, Hui DSC, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. *J Infect Dis* 2009;200:492-500.
 34. Cheng PKC, Wong DA, Tong LKL, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. *Lancet* 2004;363:1699-700.
 35. To KK-W, Tsang OT-T, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 2020;20:565-74.
 36. Zhou R, Li F, Chen F, et al. Viral dynamics in asymptomatic patients with COVID-19. *Int J Infect Dis* 2020;96:288-90.
 37. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 2020;26:672-5.
 38. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020;581:465-9.
 39. COVID-19 treatment guidelines: corticosteroids. Bethesda, MD: National Institutes of Health, 2020 (<https://www.covid19treatmentguidelines.nih.gov/dexamethasone/>).
 40. Siemieniuk R, Rochwerf B, Agoritsas T, et al. A living WHO guideline on drugs for Covid-19. *BMJ* 2020;370:m3379.

Copyright © 2020 Massachusetts Medical Society.